Cargando…
Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials
This systematic review determines the efficacy and safety of duloxetine for chronic low back pain (CLBP). We queried the PubMed, SCOPUS, and Ovid MEDLINE databases. All level I and II randomized controlled studies published in the English language investigating the efficacy of duloxetine for chronic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140818/ https://www.ncbi.nlm.nih.gov/pubmed/34046287 http://dx.doi.org/10.7759/cureus.15169 |
_version_ | 1783696251490926592 |
---|---|
author | Hirase, Takashi Hirase, Jessica Ling, Jeremiah Kuo, Peggy H Hernandez, Gilbert A Giwa, Kayode Marco, Rex |
author_facet | Hirase, Takashi Hirase, Jessica Ling, Jeremiah Kuo, Peggy H Hernandez, Gilbert A Giwa, Kayode Marco, Rex |
author_sort | Hirase, Takashi |
collection | PubMed |
description | This systematic review determines the efficacy and safety of duloxetine for chronic low back pain (CLBP). We queried the PubMed, SCOPUS, and Ovid MEDLINE databases. All level I and II randomized controlled studies published in the English language investigating the efficacy of duloxetine for chronic low back pain were included. Five studies (832 duloxetine-treated patients, 667 placebo-treated patients, and 41 duloxetine and placebo crossover analysis patients) were analyzed. One study was level I evidence and four studies were level II evidence. All five studies reported statistically significant improvements in more than one back-pain-specific clinical outcome score with duloxetine versus placebo. Four studies found that duloxetine 60 mg daily leads to one or more statistically significant improvements versus placebo in Brief Pain Inventory Severity (BPI-S) scores. All five studies found no significant difference in serious adverse events (AEs) between the duloxetine and placebo groups. One study found a higher rate of total AEs among the duloxetine 120 mg group versus the placebo group; however, the same study did not find a significant difference in total AEs among duloxetine 20 mg and 60 mg groups versus placebo. Duloxetine is a safe and effective first-line option for the treatment of CLBP. Current studies demonstrate that 60 mg taken once daily has the highest efficacy for reducing pain and disability while minimizing minor adverse effects. Further randomized controlled trials with long-term follow-up are necessary to determine its long-term effects. |
format | Online Article Text |
id | pubmed-8140818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-81408182021-05-26 Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials Hirase, Takashi Hirase, Jessica Ling, Jeremiah Kuo, Peggy H Hernandez, Gilbert A Giwa, Kayode Marco, Rex Cureus Pain Management This systematic review determines the efficacy and safety of duloxetine for chronic low back pain (CLBP). We queried the PubMed, SCOPUS, and Ovid MEDLINE databases. All level I and II randomized controlled studies published in the English language investigating the efficacy of duloxetine for chronic low back pain were included. Five studies (832 duloxetine-treated patients, 667 placebo-treated patients, and 41 duloxetine and placebo crossover analysis patients) were analyzed. One study was level I evidence and four studies were level II evidence. All five studies reported statistically significant improvements in more than one back-pain-specific clinical outcome score with duloxetine versus placebo. Four studies found that duloxetine 60 mg daily leads to one or more statistically significant improvements versus placebo in Brief Pain Inventory Severity (BPI-S) scores. All five studies found no significant difference in serious adverse events (AEs) between the duloxetine and placebo groups. One study found a higher rate of total AEs among the duloxetine 120 mg group versus the placebo group; however, the same study did not find a significant difference in total AEs among duloxetine 20 mg and 60 mg groups versus placebo. Duloxetine is a safe and effective first-line option for the treatment of CLBP. Current studies demonstrate that 60 mg taken once daily has the highest efficacy for reducing pain and disability while minimizing minor adverse effects. Further randomized controlled trials with long-term follow-up are necessary to determine its long-term effects. Cureus 2021-05-22 /pmc/articles/PMC8140818/ /pubmed/34046287 http://dx.doi.org/10.7759/cureus.15169 Text en Copyright © 2021, Hirase et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pain Management Hirase, Takashi Hirase, Jessica Ling, Jeremiah Kuo, Peggy H Hernandez, Gilbert A Giwa, Kayode Marco, Rex Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials |
title | Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials |
title_full | Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials |
title_fullStr | Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials |
title_full_unstemmed | Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials |
title_short | Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials |
title_sort | duloxetine for the treatment of chronic low back pain: a systematic review of randomized placebo-controlled trials |
topic | Pain Management |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140818/ https://www.ncbi.nlm.nih.gov/pubmed/34046287 http://dx.doi.org/10.7759/cureus.15169 |
work_keys_str_mv | AT hirasetakashi duloxetineforthetreatmentofchroniclowbackpainasystematicreviewofrandomizedplacebocontrolledtrials AT hirasejessica duloxetineforthetreatmentofchroniclowbackpainasystematicreviewofrandomizedplacebocontrolledtrials AT lingjeremiah duloxetineforthetreatmentofchroniclowbackpainasystematicreviewofrandomizedplacebocontrolledtrials AT kuopeggyh duloxetineforthetreatmentofchroniclowbackpainasystematicreviewofrandomizedplacebocontrolledtrials AT hernandezgilberta duloxetineforthetreatmentofchroniclowbackpainasystematicreviewofrandomizedplacebocontrolledtrials AT giwakayode duloxetineforthetreatmentofchroniclowbackpainasystematicreviewofrandomizedplacebocontrolledtrials AT marcorex duloxetineforthetreatmentofchroniclowbackpainasystematicreviewofrandomizedplacebocontrolledtrials |